slides · global inventory
Clinical Trial Design
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 129
Current window 61-90
Pages 5
Rows per page 30
Framework
61-90 of 129
45
The slide uses a process flow diagram to illustrate the study design (Part A to Part B).23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
35
The slide uses a flow diagram to illustrate the randomization process and study timeline.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach1 hit
36
The slide uses a process flow diagram to illustrate the clinical trial structure.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
37
The slide uses a process flow diagram to illustrate the clinical trial structure.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
17
The slide outlines a clinical trial timeline and key efficacy metrics for a chronic hepatitis B (cHBV) treatment.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
22
The slide outlines a multi-stage clinical trial process including patient identification, open-label, and placebo-controlled phases.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
22
The slide uses a process flow diagram to illustrate the clinical trial methodology.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
22
The slide outlines a multi-stage clinical trial process including an open-label phase followed by a placebo-controlled relapse-based study.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
23
The slide outlines a multi-stage clinical trial process including patient identification, open-label, and placebo-controlled phases.argenx SE | Investor Presentation Deck | 23 slides · argenx
Conference presentation Investor relations Beat · New Bliss1 hit
24
The slide uses a process flow diagram to illustrate the clinical trial structure.argenx SE | Investor Presentation Deck | 26 slides · argenx
Conference presentation Investor relations Beat · Resolution1 hit
25
The slide outlines a multi-phase trial structure with specific cohorts (IMNM, ASyS, DM) and a GO/NO-GO decision point.argenx SE | Investor Presentation Deck | 26 slides · argenx
Conference presentation Investor relations Beat · Resolution1 hit
12
The slide uses a standard clinical trial process flow diagram.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
35
The slide outlines the clinical trial methodology, specifically the randomization and treatment arms for advanced endometrial cancer.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
51
The slide uses a standard clinical trial flow diagram (randomization, intervention, surgery, follow-up).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
13
The slide uses a standard clinical trial flow diagram to illustrate the study protocol.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
12
The slide uses a standard clinical trial flow diagram to illustrate the study protocol.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
12
The diagram outlines the randomization, treatment regimen, disease progression assessment, and study endpoints.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
24
The slide outlines a randomized clinical trial structure with two arms (CTX-009 + Paclitaxel vs Paclitaxel alone) and a crossover provision.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
24
The slide outlines a 2:1 randomized clinical trial structure for a drug combination (CTX-009 + Paclitaxel) versus a control (Paclitaxel).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
The slide outlines a standard oncology clinical trial design (Dose Escalation to RP2D to Dose Expansion).Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
18
The slide outlines a randomized, open-label trial comparing Olvi-Vec + Platinum-doublet + Bevacizumab against a standard comparator arm.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
37
The slide outlines a clinical trial design using a dose-escalation process leading to MTD/RP2D expansion cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
12
The slide outlines a clinical trial process flow from initial NSCLC 2L+ patient entry through randomization to expansion.MAIA Biotechnology | Investor Presentation Deck | 35 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Why Now1 hit
21
The slide outlines a clinical trial design using a basket/umbrella approach to test THIO in combination with various anti-PD-1/PD-L1 therapies.MAIA Biotechnology | Investor Presentation Deck | 35 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
15
The slide uses a timeline-based process diagram to illustrate the clinical trial structure.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations 1 hit
112
The slide outlines a two-part clinical trial design (Part 1 and Part 2) with specific enrollment criteria and outcome measures.Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides · Recursion Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit